Guardant Health, Inc. (GH)

NASDAQ: GH · Real-Time Price · USD
65.33
+0.07 (0.11%)
Oct 10, 2025, 1:43 PM EDT - Market open
0.11%
Market Cap8.15B
Revenue (ttm)828.85M
Net Income (ttm)-413.82M
Shares Out 124.71M
EPS (ttm)-3.35
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,196,755
Open66.57
Previous Close65.26
Day's Range64.30 - 66.57
52-Week Range20.14 - 68.00
Beta1.53
AnalystsStrong Buy
Price Target64.91 (-0.64%)
Earnings DateOct 29, 2025

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p... [Read more]

Sector Healthcare
IPO Date Oct 4, 2018
Employees 2,021
Stock Exchange NASDAQ
Ticker Symbol GH
Full Company Profile

Financial Performance

In 2024, Guardant Health's revenue was $739.02 million, an increase of 31.04% compared to the previous year's $563.95 million. Losses were -$436.37 million, -8.98% less than in 2023.

Financial Statements

Analyst Summary

According to 22 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price target is $64.91, which is a decrease of -0.64% from the latest price.

Price Target
$64.91
(-0.64% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Guardant Health to Report Third Quarter 2025 Financial Results on October 29, 2025

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2025 after market c...

21 hours ago - Business Wire

FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo™ (imlunestrant) for Treatment of ESR1-mutated Advanced Breast Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved its ...

11 days ago - Business Wire

Guardant Health, Inc. (GH) Analyst/Investor Day Transcript

Guardant Health, Inc. (NASDAQ:GH) Analyst/Investor Day September 24, 2025 9:00 AM EDT Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Co-Founder, Co-CEO & ...

15 days ago - Seeking Alpha

Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant's Shield™ Blood-based Screening Test in the United States

PALO ALTO, Calif. & SECAUCUS, N.J.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest Diagnostics (NYSE: DGX), a leader in diagnostic informa...

Other symbols: DGX
16 days ago - Business Wire

Alex M. Azar II Joins Guardant Health Board of Directors

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective im...

24 days ago - Business Wire

Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has reached a strategic agreement with LabFlorida/SunDx Labs to...

4 weeks ago - Business Wire

Guardant Health, Inc. (GH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Guardant Health, Inc. (NASDAQ:GH) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT Company Participants Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman AmirAli Tal...

4 weeks ago - Seeking Alpha

Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic partnership with PathGroup, one of the nation's leadin...

4 weeks ago - Business Wire

Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a positive clinical readout update assessing the performance of th...

5 weeks ago - Business Wire

Guardant Health to Host Investor Day on September 24, 2025

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be hosting an Investor Day on September 24, 2025, in New ...

6 weeks ago - Business Wire

Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Morgan Stanley 23rd Annual Gl...

6 weeks ago - Business Wire

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on July 22, 2025, the Compensation Committee of Guardant's Board of D...

7 weeks ago - Business Wire

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

We added key positions in Masimo, Exact Sciences, Eli Lilly, Penumbra, and Edwards Lifesciences, each with strong growth drivers and market leadership. Our investment in Masimo is supported by divesti...

2 months ago - Seeking Alpha

American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

SAN FRANCISCO--(BUSINESS WIRE)---- $GH--The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision oncology company focused on improving...

2 months ago - Business Wire

Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Canaccord Genuity 45th Annual...

2 months ago - Business Wire

Guardant Health Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Earnings

Guardant Health, Inc. GH reported better-than-expected second-quarter financial results and raised its FY25 sales guidance above estimates on Wednesday.

2 months ago - Benzinga

Guardant Health, Inc. (GH) Q2 2025 Earnings Call Transcript

Guardant Health, Inc. (NASDAQ:GH) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants AmirAli Talasaz - Co-CEO & Director Helmy Eltoukhy - Co-Founder, Co-CEO & Chairman Mic...

2 months ago - Seeking Alpha

Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 ...

2 months ago - Business Wire

Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and health advocate James Van Der Beek ...

2 months ago - Business Wire

New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the first clinical readout from their collaboration in the RADIOHE...

2 months ago - Business Wire

First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute...

3 months ago - Business Wire

Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2025 after market ...

3 months ago - Business Wire

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named...

4 months ago - Business Wire

New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the...

4 months ago - Business Wire

Why Is Cancer Diagnostic Guardant Health Stock Trading Higher On Tuesday?

Guardant Health, Inc. GH stock is trading higher on Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the company's Shield multi-cancer detection (MC...

4 months ago - Benzinga